Soligenix Inc., a Princeton-based biopharmaceutical company, announced Wednedsay it has named Jonathan Guarino as its senior vice president and chief financial officer.
Guarino has more than 20 years of experience in managing emerging growth and commercial companies.
“We are delighted to welcome Jonathan to our team, as we leverage his combination of financial acumen and commercial and business experience,” Christopher J. Schaber, CEO and president of Soligenix, said. “As we continue to execute our growth strategy, we are clearly building momentum towards potential commercialization and the talent we are attracting is an absolute reflection of our solid progress to date.”
Before his appointment, Guarino served as corporate controller for Hepion Pharmaceuticals Inc., formerly ContraVir Pharmaceuticals. Previously, he worked as controller and senior manager of technical accounting for Suite K Value Added Services LLC and Convance Inc. He also held accounting and financial positions of increasing responsibility at several companies including PricewaterhouseCoopers LLP, BlackRock Inc. and Barnes & Noble Inc.
“I am excited about Soligenix’s potential to become a commercial company and am thrilled to be joining the company at this pivotal time. I look forward to helping the company achieve success and create additional value,” Guarino said.